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transplant, the answer would be obvious. However, if we asked
transplant surgeons, as many as 70% might say, "it doesn't
matter." Naturally we assume that surgeons have their pa-
tients' interests at heart; yet on this point, these doctors seem to
react irrationally. Is it because the surgeons want to reserve the
right to decide who gets the transplant without having a "lowly
tissue typer" dictate what to do? Or do the surgeons have valid
reasons for thinking that if the process was inadequate 20 years
ago, it must still be worthless?
Tissue typing
Case presentation
The patient is an obese, 100 kg female who has been awaiting renal
transplantation for 3 years. She is highly sensitized because of prior
pregnancies, and her panel of reactive antibodies has been 90% for the
past 3 years.
A cadaver kidney with a 6-antigen match is offered from a distant
center. The kidney, from an 8-year-old girl who sustained head injuries
in an automobile accident, is HLA type Al, A3, B7, B8, DR2, DR3. The
process of transfer, crossmatch, and implantation would entail approx-
imately 30 hours of cold ischemia time.
Not using this kidney could mean more years of waiting. On the other
hand, with 30 hours of cold ischemia time and a highly sensitized
patient, are the chances of success too low to take? Does it really matter
that the kidney is only 6-antigen matched?
Discussion
DR. PAUL I. TERASAKI (Department of Surgery, UCLA
School of Medicine, Los Angeles, California): The controversy
over the value of HLA matching for recipient selection in
cadaveric renal transplantation has persisted for 20 years [1].
This controversy is one of the longest-unresolved issues related
to transplantation. Why has reaching a consensus taken so
long? Has the issue finally been resolved?
If we were to ask patients if they preferred a matched
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Knowledge about HLA typing has increased enormously
over the last 20 years, partly because the field of transplantation
also developed rapidly. Analysis of HLA matching 20 years
ago, when only 11 antigen specificities were known, cannot be
compared to analysis today, when 100 or so specificities are
known. The remarkable growth in the body of our HLA
knowledge is apparent from the 10 International Histocompat-
ibility Workshop volumes published over the past 25 years.
Specific improvement in the detection of each of the HLA
specificities is best documented in the results of the Interna-
tional Cell Exchange. Every month for the past 15 years,
lymphocytes from 4 individuals have been shipped from our
laboratory for "blind" testing. Throughout the world, 288
laboratories participate in this voluntary quality-control ex-
change. Improvement in detection of each of the specificities
has been demonstrated and tracked [2]. Figure 1 shows the
detection of 4 HLA antigens represented in one person over a
13-year period. When his blood sample was submitted in 1975,
HLA-A1 1 antigen was detected by approximately 90% of the
laboratories. The A23 and B38 antigens were detected by 51%
and 14% of the laboratories respectively. When the same
person's cells were distributed 13 years later, correct typing for
all 4 of his antigens was accomplished by more than 90% of the
laboratories.
On the basis of 157 such cell exchanges over the past 15
years, the HLA specificities have been classified into well-
defined antigens and developing antigens (Table 1). By shipping
lymphocytes "blindly" from 628 people to more than 200 tissue
typing laboratories, the percentage of agreement among labo-
ratories was established for the HLA specificities listed. Some
of the specificities were very well defined, in that 95% to 100%
of the typing laboratories could identify them correctly. Many
other specificities were detected by fewer than 50% of the labs,
however, and thus currently are labeled as "developing" anti-
gens. Clearly, standardization of all specificities in all laborato-
ries is still incomplete.
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Fig. I. Development of agreement among tissue typing laboratories.
Over the past 13 years, lymphocytes from the same person were
shipped "blind" to 100—250 tissue typing laboratories. The percentage
of agreement in assignment of the specificities increased with time. For
the past 15 years, more than 600 technicians have been tested "blindly"
by the International Cell Exchange.
The inability of a laboratory to detect antigens is primarily a
function of the antisera available for typing and is not a
reflection of the technical capabilities of the laboratory. The
standard tissue typing technique [31 is relatively simple; with
minimal training, most technicians can readily master the
methods. The antisera defining each of the specificities, on the
other hand, have been extremely difficult to obtain and distrib-
ute widely. Although there are many serum exchange programs
and many commercial companies active in this field, the prob-
lem of making high-quality reagents identifying each of the
specificities remains challenging. To date, even the introduction
of monoclonal antibody methodology for producing antibodies
has met with relatively minor success in providing antibodies to
the rare specificities.
Thus, 25 years after the inception of the field of tissue typing,
the basic work that would enable all laboratories to perform
uniform typing, that is, having all the reagents for the known
specificities, has not yet been perfected. Moreover, many
antigens of new loci such as DQ and DP within the same
histocompatibility complex have been discovered, but their
relevance to clinical transplantation is as yet undetermined. For
purposes of this discussion, therefore, we are forced to ask,
"Has state-of-the-art tissue typing as it existed during the past
5 years (since the introduction of cyclosporine A) been useful in
clinical transplantation?"
The six-antigen-match program. In November 1987, all trans-
plantation programs in the United States agreed to share
kidneys for 6-antigen (HLA)-matched recipients. The 16,000
potential recipients were entered in a central computer pool at
the United Network for Organ Sharing (UN OS) headquarters in
Richmond, Virginia. Whenever a donor was identified any-
where in the United States, the tissue type was entered into the
computer; if a matched recipient existed, the donor center was
obliged to offer one of the donor's kidneys [41. (The other
kidney was usually reserved for transplantation at a nearby
location.) Our need for urgent information on the progress of
this national effort prompted us to institute a series of question-
naires to evaluate the program. Transplant center data coordi-
nators supplied information on transplant date, graft removal,
Table 1. Percentage of agreement among more than 200 tissue typing
laboratories in detecting HLA specificities
Well-
defined
antigens Developing antigens
(95%—100%) (80%—94%) (50%—79%)
Al AWI9 AW36 AW66
A2 A23 - AW68
A3 A25 BW47 AW69
A9 A26 BW52 AW74
AlO A30 BW53 —
All A31 BW55 BW46
A24 A32 BW56 BW54
A28 AW33 BW57 BW64
A29 AW34 BW58 BW71
- - BW59 BW72
B7 B5 BW61 BW73
B8 B17 BW63 BW75
B12 BW22 BWÔ5 BW76
B13 B35 BW67 —
B14 B37 BW7O CW5
B15 B38 - CW6
B16 B39 CW1 CW7
B18 BW41 CW2 CW8
B21 BW42 CW3 CW9
B27 B45 CW4 CWIO
B40 BW48 - CWI1
B44 B49 — —
— BW5O - -
- B51 - -
- BW6O - -
- BW62 - -
patient death, transplant number, age, race, transfusions, pan-
el-reactive antibody, warm and cold ischemia times, preserva-
tion methods, and HLA typings. The results of the second
questionnaire were published in 1989 [5]. Here we report on the
results of the third questionnaire. We obtained 776 replies on
243 recipients of 6-antigen-matched kidneys. Data were re-
ceived from 93 donor centers and 98 recipient centers.
The median cold ischemia time for 6-antigen-matched kid-
neys was 25 to 30 hours, as compared with 19 to 24 hours for
non-antigen-matched control kidneys (Fig. 2). The controls
were transplants performed from local donors in the same time
period, as reported to the UCLA Registry. The longer time
taken to transport the 6-antigen-matched kidneys is reflected in
increased cold ischemia time. Even in kidneys with cold isch-
emia times longer than 24 hours, however, the graft survival at
one year was higher in the 6-antigen-matched transplants than
in non-matched transplants with less than 24 hours of cold
ischemia (Fig. 3). For regrafts, longer cold ischemia time also
was not deleterious to the 6-antigen-matched transplants. Thus
the concern that ischemic damage imposed by shipping would
cancel out the effect of good matching is unfounded. Instead,
with 6-antigen matching, the reversible injury produced by cold
ischemia became inconsequential.
Although no deliberate effort was made to perform trans-
plants in sensitized recipients, the 6-antigen-match program
unexpectedly resulted in many highly sensitized patients receiv-
ing transplants. (Sensitized patients were defined as those with
antibodies reactive against 80% of the panel). For many years,
we have seen a marked tendency for transplant centers to
preferentially offer transplants to patients who are not sensi-
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tized [61. As Figure 4 shows, only 35% of the transplants in the
UCLA Registry controls were given to sensitized patients,
whereas as many as 72%of the 6-antigen-matched kidneys were
grafted into sensitized patients. Moreover, as many as 25%of
the 6-antigen-matched kidneys were grafted into patients with
more than 90% panel-reactive antibodies. This high percentage
of transplants grafted into sensitized patients probably resulted
from the fact that these patients had negative crossmatches with
the well-matched donors. Most importantly, the distribution of
6-antigen-match transplants into sensitized recipients mirrors
the distribution of sensitized patients in the national pool. It
would appear that the decision to transplant a kidney into a
particular patient was made as though sensitization did not
exist.
The high survival rate of transplants in highly sensitized
patients receiving 6-antigen-matched transplants has been most
impressive (Fig. 5). This favorable outcome was evident both
for first and subsequent grafts. As Figure 5 shows, graft survival
rates were higher in sensitized patients receiving 6-antigen
matches than in non-sensitized control patients. Actually, in
patients who had less than 80% preformed cytotoxic antibodies,
the 6-antigen-matched first grafts had a 97% one-year graft
survival. Thus, although sensitization does affect the outcome
of 6-antigen-matched transplants, matching overcomes the ef-
fect of sensitization.
The overall graft survival of 6-antigen-matched transplants
compared with the non-shipped, unmatched controls from the
UCLA Registry is given in Figure 6. The difference between
graft survival for both first and subsequent grafts was statisti-
cally significant at one year. Considering that the 6-antigen-
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Fig. 2. Distribution of cold ischemia times in
the 6-antigen-matched kidneys and the UCLA
controls. Most of the kidneys in the 6-antigen-
matched group were shipped, whereas those
in the control groups were used locally.
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Sensitization levels
matched transplants were performed in 98 different centers of
varying experience, the 91% one-year graft survival is very
impressive. The initial apprehension about what would happen
to kidneys shipped from unknown surgeons at 93 donor centers
also has been shown to be groundless. Further, kidney harvest-
ing methods and surgical transplantation techniques are now
widely standardized sufficiently and equally successful nation-
wide. Thus, in this setting, matching for 6 HLA antigens
becomes paramount. Tissue typing, performed at more than 100
locations connected with the transplant centers and donor
centers, also must have been performed properly, for kidneys
shipped and transplanted according to tissue types had this
exceptional survival rate.
Although relatively few contralateral renal transplants were
available for analysis (Fig. 7), early results indicate that the
6-antigen-matched kidney had a significantly higher graft sur-
Fig. 4. Distribution of sensitization levels of
patients receiving 6-antigen-matched
transplants. As shown by the controls, most
transplants are placed into nonsensitized
patients. The distribution of sensitized
patients in the waiting pools is similar to that
of patients who had received 6-antigen-
matched kidneys.
Fig. 5. Graft survival in highly sensitized
patients. The graft survival of 6-antigen-
matched transplants into highly sensitized
patients was higher than that of control
transplants into nonsensitized patients.
viva! than did the contralateral kidney. In the 43 pairs of
kidneys in which one kidney had been used for a 6-antigen
match, 100% survival was obtained both for the first and
subsequently grafted kidneys, The contralateral kidneys for the
first graft had a 78% one-year graft survival, as might have been
expected from the Registry control data. These kidneys had not
been shipped, so one could anticipate that the survival rate of
these grafts would be the same as that for other non-shipped
kidneys into mismatched recipients. Only 4 of the contralateral
kidneys were placed in patients receiving subsequent grafts, so
we can draw no conclusions from these limited data.
BDR matching. Although one often hears that the advent of
cyclosporine has precluded the need for HLA matching, nu-
merous studies show that even with cyclosporine, HLA match-
ing results in improved survival rates [7—9]. The large registry
studies are quite uniform in their results, with a 10% to 15%
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difference in one-year graft survival between the best- and
worst-matched transplants. Figure 8 illustrates our own most
recent analysis. As I noted earlier, patients with no BDR
mismatch clearly had a better survival rate than did those in
whom 4 BDR antigens were mismatched. We found a 2% to 3%
difference in one-year graft survival for each additional mis-
matched antigen.
Using data similar to this that existed 3 years ago, the UNOS
agreement called for the selection of recipients on the basis of a
point system [101. It gave 10 points each for HLA match,
waiting time, and preformed antibodies. The point system was
subsequently modified to give 1.0 point for waiting time, 0.5
point for each additional year of wait, and 4 points for a
negative crossmatch. The results of transplants stratified by the
current UNOS point system are shown in Figure 9. In consec-
utive renal transplants performed in 1988 and 1989 by transplant
centers in Los Angeles without the use of a point system, 99%
of the transplants had one or more BDR-mismatched antigens
(top bar). Utilizing the UNOS point system on the contralateral
kidney among 135 patients, 17% had zero ABDR mismatches
and an additional 4% had zero BDR-mismatched grafts. Selec-
tion of the recipient of the contralateral kidney was from a pooi
of 1000 patients. If the waiting pooi of 16,000 patients in the
United States is considered, as many as 33% could receive zero
ABDR-mismatched grafts, and an additional 41% could receive
zero BDR-mismatched transplants (lower bar). Using a national
sharing system, only 26% of recipients would have one or more
BDR mismatches, as compared with 99% in the current expe-
rience at most centers.
Should HLA matching be used to select recipients?
Now we arrive at the central question. Given the available
data, should we use the HLA system for matching? If so, to
what extent should we rely on it? The massive collaborative
trial involving 98 centers and utilizing 98 different immunosup-
pressive protocols has yielded better graft survival rates, which
are similar in fact to those at the 7 most successful transplant
centers nationwide. Further, the 6-antigen-match data show
that we can no longer ignore the value of HLA typing. The
extremely high graft survival rate obtained—even when kidneys
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Fig. 9. Distribution of HLA matches in
kidneys of the Los Angeles Transplant Society
and potential distribution on a national basis.
From each cadaver donor at every transplant
center, one kidney was transplanted according
to the UNOS point system and the other by a
non-point system. When transplanted by the
non-point system, 99% of the grafts were one
or more BDR mismatched. When the UNOS
point system was used in 135 grafts, this
fraction was decreased to 79%. As shown in
the bottom bar, if kidneys were shared in the
national pool, 74% could be transplanted into
zero ABDR or zero BDR mismatched
recipients.
were shipped to distant centers and with longer cold ischemia
times—clearly shows that tissue typing can be successfully
applied to clinical renal transplantation. Recipients had been
typed and entered into the computer by 98 different recipient
typing laboratories, and donors were typed at 93 different donor
laboratories, Based on these typings, the 6-antigen-matched
pairs were identified. After shipping kidneys, experience with
random donor transplants shows that it would be impossible to
obtain a 90% one-year graft survival simply by chance.
Some critics have argued that these analyses depend on
questionnaires, that other analyses of the UNOS Registry had
shown that the 6-antigen-matched grafts had the same survival
rate as did non-matched controls, and that not every patient has
been accounted for. Although it is true that data on every
patient have not yet been received, we believe that the study's
validity has not been affected by any deliberate omission of data
on failures. Thus, assuming that reporting of results has not
been selective, the overall conclusions should remain the same
as when each and every transplant is eventually accounted for.
Similarly, the one-year graft survivals from the voluntary
UCLA Kidney Transplant Registry did not differ significantly
when compared with the mandatory UNOS Kidney Transplant
Registry. The UCLA one-year graft survival was 77%; the
UNOS Registry for the same time period (November 1987 to
November 1989) was 76% for 6542 and 7049 recipients of a first
graft from a cadaveric donor, respectively. If we assume that
the centers with good and bad results did not participate in the
UCLA studies in a selective way, then we could expect that the
overall rate of survival would not differ from that obtained by a
mandatory registry. Of course, the registry data are based on
much larger numbers than those available in the 6-antigen-
match study. We take heart in the fact that despite increasing
the number of patients in the 6-antigen-match study from 88 to
123 to 243 cases in the 3 series of questionnaires, the one-year
graft survival rate has remained essentially the same, namely,
89% to 90%.
The success of the collaborative program also means that
we should not "back-track" to earlier positions of either
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dispensing with tissue typing or using it only as a convenient
tool for rationalization of choices made on other grounds. For
the tissue typing laboratories, it also means that typing must be
performed and reported accurately, both for recipients and
donors, any time of day or night. Long years of neglect of
typing on the part of transplant surgeons has led to the feeling
by some that typing results do not matter much in any event.
Attempts at documenting and retesting donors and recipients to
identify sources of error will have to be expanded. Collabora-
tive workshops currently underway to recheck the typing on
well-matched pairs is one example.
An unexpected windfall of the 6-antigen-match program has
been the transplantation of kidneys into so many highly sensi-
tized patients, with excellent results. In the past, no attempt
had been made to select these patients, but 6-antigen matching
avoids the problem of positive crossmatches in many highly
sensitized patients. I strongly believe that obtaining well-
matched transplants is unquestionably the best solution for the
highly sensitized patient, for there is simply no mismatch
against which the antibodies can react.
In short, tissue typing is here to stay. Complaints about the
"tyranny" of tissue typing can be equated with the tyranny of
the ABO system in blood transfusions. We must use HLA
matching in recipient selection, although we have not yet solved
the question of what the extent should be.
Should the UNOS point system be continued? Some clini-
cians have voiced opposition to the UNOS point system on the
ground that in different series of analyses, the difference be-
tween antigens of mismatch has not been additive, and there-
fore the point system, which emphasizes HLA matching,
should be discontinued [11]. In a larger series of patients from
the UCLA Registry, as I mentioned earlier, there is a general
tendency for patients with few mismatches to have higher graft
survival. Similar data have been published from the Collabora-
tive Transplant Studies [7] and from Eurotransplant [8]. For a
few differing percentage points in one-year graft survival, the
argument runs, should we be using this system to select
patients?
Approximately 1000 patients are waiting for kidney trans-
plants in Los Angeles alone. If a donor were to become
available tonight, which of the 1000 patients should we select?
Obviously, a system should be in place to prevent anarchy. The
city could be geographically divided into its 10 transplant center
regions, and kidneys obtained at one center and its affiliated
community hospitals could be designated for a recipient regis-
tered at that particular center. This is the center-driven concept
of recipient selection. Similarly, the United States could be
divided according to the boundaries of transplant centers and
recipients registered in each area. The patient-driven system is
based on equitable transplantation for patients, independent of
the center and the selection by surgeons. The National Trans-
plant Act of 1987 addressed this question and developed en-
abling legislation resulting in the creation of UNOS.
The entire field of transplantation started with the transplant
center-directed concept. Clearly, the field depends on the
interest and drive of physicians involved in the transplantation
process. It is possible that either the field is transplant-surgeon-
driven or not driven at all. Some have argued that the clamor to
have a patient-driven system might be misdirected, because
ultimately it is the surgeon who must find the kidneys and
perform the transplant.
The UNOS point system, first suggested by Starzl, proposed
that equitable distribution of scarce kidneys could be accom-
plished by assigning varying points to the relevant factors [10].
Only 4 factors were deemed important: HLA matching, level of
sensitization, waiting time, and medical urgency. Medical ur-
gency was subsequently deleted; it was generally agreed that
the current state of dialysis made this category unnecessary.
Strict use of the point system obviates consideration of a
patient's age, gender, educational background, socioeconomic
condition, referral by influential people, or numerous other
extenuating circumstances. A drug addict could get preference
over a medical student. A completely impersonal system would
be instituted; once in place, it would be difficult to displace or
subvert. Transplant surgeons, who traditionally have had the
opportunity to make the choices, would have to relinquish their
authority to a computer that would list the choices in decimals
out to the hundredth place, perhaps placing the patient who
receives the kidney ahead of another patient by only 0.01 point.
Is this system reasonable when the difference is only a few
percentage points between the one-year graft survival for each
level of mismatch? I agree with the objection. The UNOS point
system should not be used today to obtain this "ultrafine" level
of discrimination. Instead, I'd like to propose an alternative.
Proposed use of HLA matching. Because of (1) the current
level of knowledge and development of HLA matching, and (2)
the limited pool of organ donors, I believe that the rationale for
the current UNOS point system is not very strong. I would like
to propose the following mechanism for designating organ
recipients: Each transplant center will keep one donor kidney,
to be transplanted as it sees fit, and the other kidney will be
given to the national pool for distribution according to the
UNOS point system. The system is similar to that used in Los
Angeles, except that under this new system, one kidney would
not be used for the best-matched patient in Los Angeles, but
rather for the best-matched patient in the entire United States.
With the expansion of the pool of 1000 waiting recipients in Los
Angeles to 16,000 in the United States, the quality of matching
will markedly improve. Mickey has calculated that as many as
74% of the patients would receive kidneys with zero ABDR or
zero BDR mismatches (Fig. 9) [121. Almost all patients who
receive a kidney from the national pool could receive kidneys
that have no DR mismatch. In the 26% of instances in which a
zero BDR match is not found, the prerogative for choosing a
recipient could revert back to the donating center. Donation
points (30 per kidney) would be awarded to the donating center,
to be apportioned equally among all its potential recipients.
With this method, transplant centers would still have the
incentive to look for cadaver donor kidneys and to maintain an
active program. In addition, they would have an opportunity to
select patients according to their own criteria, at least for one of
each donor's kidneys.
The UNOS 6-antigen-match agreement would automatically
be included in the proposal. Agreements among centers in any
given city or sharing region would be simplified: one kidney
would stay at the center; the other would go to the national
pool. The number of kidneys sent into the pool would be
expected to be returned to each center on a statistical basis, in
564 Nephrology Forum: HLA typing in renal transplantation
proportion to the waiting patients at each center and according
to the donations from that center.
This proposal addresses the main argument against the
UNOS point system, that is, that the survival rate difference
among the different degrees of mismatch is not large. It permits
the true utilization of HLA matching in selecting the best
matches. In small local poois, it is almost impossible to obtain
good matches, and use of small point differences between
poorly matched grafts probably can be questioned. However, if
the kidneys were to be sent to zero-BDR-mismatched recipi-
ents, the point system can be justified.
This proposal is a compromise between patient-driven and
center-driven systems. Moreover, the proposed system works.
For more than 20 years, a modification of this approach has
been used by 10 transplant centers in the Los Angeles area [131.
The system has not been a total success in Los Angeles because
even with a pooi size of 1000 patients, good HLA matches could
not always be achieved. In many areas of the country, trans-
plant centers already share kidneys locally. The proposal
entails only a minor modification—that the kidneys be shared
nationally. As shown by the 6-antigen-match study, the in-
creased cold ischemia time imposed by national sharing did not
adversely affect the one-year graft survivals.
Summary. Over the past 25 years, HLA typing has developed
steadily so that tissue typing laboratories throughout the world
can uniformly identify many antigenic specificities. As part of
an agreement among all transplant centers in the United States,
for the past 2 years kidneys have been shipped transcontinen-
tally, based on tissue typing. The UNOS agreement mandated
that 6-antigen-matched grafts would be shared. Among 133 first
grafts, 91% one-year graft survival was obtained, as compared
with 78% for control kidneys that had not been shipped. For 43
patients receiving subsequent grafts, one-year graft survival
was 82%.
Six-antigen-matched kidneys with more than 24-hour-cold
ischemia time had a one-year graft survival rate of 91%; thus
shipping had not adversely affected the matched transplants. As
many as 72% of the 6-antigen-matched kidneys were grafted
into sensitized patients, and 25% were transplanted into pa-
tients with more than 90% panel-reactive antibodies. Even in
the 18 patients with more than 80% panel-reactive antibodies,
the one-year graft survival was 87%.
On the basis of this successful experience with shipping
kidneys to matched patients, I propose that one kidney from
each donor be kept by the center and the other be shared in the
national pool. If this were done, 33% of the recipients of the
pooled kidneys could receive a zero-ABDR-mismatched trans-
plant, and another 41% could receive a zero-BDR-mismatched
graft. The "keep one, share one" system has worked success-
fully in many areas in the past, should not impose a hardship on
transplant centers, and should provide the greatest good for the
greatest number.
Questions and answers
D. JOHN T. HARR!NGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): I have two ques-
tions. First, what kind of care does the kidney receive in transit
according to the new UNOS system? I am specifically inter-
ested in solutions used, temperature controls, etc. Second, can
one demonstrate a reduced need for immunosuppression with a
6-antigen-matched kidney?
DR. TE1sAKI: The kidneys for the 6-antigen matches were
essentially all stored in Collins solution, which we developed in
the UCLA Tissue Typing Laboratory 20 years ago for the
purpose of shipping kidneys to matched recipients [14]. Some
aspects of preservation, such as being certain that kidneys are
well perfused with solution, are difficult to standardize. Despite
the variables in organ salvaging techniques, perfusion methods,
and longer cold ischemia times, the one-year graft survival with
the 6-antigen-matched transplants was 90%. Possibly the new
Belzer solution from the University of Wisconsin will permit
even longer kidney storage.
With respect to immunosuppression, we assume that each
center used its own protocols. Most impressive is the fact that
even though more than 100 different methods of immunosup-
pression were used, the overall one-year graft survival was 90%
in these well-matched transplants.
DR. HARRJNGTON: If one compares the 6-antigen-matched
kidney shipped across the country with the contralateral kidney
that is used locally, can one demonstrate a difference in
outcome? That is, are the shipped kidneys often not used
because of long preservation time?
DR. TE1tksAK!: The 6-antigen-matched kidneys shipped
across the country had statistically significantly higher graft
survival than did the kidneys used locally. If we consider that
most of the 6-antigen-matched kidneys were transplanted into
white patients, we could limit the contralateral kidney results to
only those obtained from white donors. Even with this adjust-
ment, the 6-antigen-matched kidneys had superior survival
rates. Shipped kidneys usually are not discarded because of
long cold ischemia times, In the case of a positive crossmatch,
the kidney is returned. I firmly believe, however, that rather
than return the kidney, one should use it in a "back-up" patient
who has no preformed cytotoxins.
DR. NICOLAOS E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): Is
there any evidence, whether experimental or clinical, that
transplantation across gender barriers for the same degree of
antigen compatibility makes a difference in terms of graft
survival?
DR. TERASAKI: Yes, there is evidence from experimental
mouse skin grafts that male donors have a gender-associated
antigen that functions as a transplant antigen [15]. A similar
antigen has not been clearly demonstrated in humans, however.
We have not seen any evidence of a male-associated antigen in
the clinical kidney transplant experience.
Nevertheless, we have noted an interesting phenomenon in
the lower graft survival of kidneys from female donors into male
recipients. We believe this effect is due to size mismatching,
rather than to an immunologic antigen present in females.
Female kidneys are generally smaller than male kidneys, and
when considered in the aggregate, these slightly lower graft
survival rates might be expected when transplanting from a
small donor into a larger recipient. We noted similar lower graft
survival when the donor was as young as 6 years of age
regardless of the gender.
DR. ANDREW S. LEVEY (Division of Nephrology, New En-
gland Medical Center): You have shown us that if we use
matching as the criterion for distributing kidneys, we will
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perform transplantation in more highly sensitized patients than
if we don't; this strategy would shorten the waiting time for
those patients. Is there a possibility that we will actually
lengthen the wait for other patients because they have an
infrequent genotype?
DR. TERASAKI: Yes, if a certain patient receives a transplant,
another patient will have to wait longer. But the 6-antigen-
match program assures that when we serendipitously find a
well-matched donor for a recipient, that recipient will be given
preference. In addition, most of the time highly sensitized
patients are unable to receive a transplant because they have
antibodies reactive to the random population. When a 6-anti-
gen-matched donor is identified for these patients, they are
given preference. As the results show, this practice has resulted
in successful transplantation in many highly sensitized patients.
One might argue that highly sensitized patients represent a
small fraction of the total waiting patients. We believe that, on
balance, the 6-antigen-match program is extremely important
for these patients and for the entire transplant program. First,
for the sensitized patients, this is the only way they will receive
a graft that will survive for a long period. Obtaining transplants
with a negative crossmatch only guarantees freedom from
hyperacute rejection, although the patients cannot be assured of
a long-surviving transplant. For those who receive the 6-anti-
gen-matches, there are indications that the half-life of the graft
will be almost 20 years. This will mean that the kidneys will be
well utilized, as compared to transplantation using a random
donor, which results in a 7- to 8-year half-life. Because kidneys
are such a valuable and scarce resource, every effort should be
made to maximize the useful life of each cadaver donor organ.
D. LEVEY: Can we estimate the average waiting time for the
population using HLA matching as the primary criterion for
organ distribution and compare that estimate with the waiting
time in practices in which there is no sharing?
DR. TERASAKI: Whether or not HLA matching is used as the
criterion, the average waiting time will be exactly the same.
This is because the average waiting time is controlled by the
number of donors available relative to the size of the patient
waiting pool.
Some critics have argued that the waiting time for certain
patients might be longer if HLA matching is used. For example,
patients with rare HLA types would have a longer wait than
would those with common HLA types. One argument is that
allocation should be random so that patients with rare types and
those with common types would have an equal chance at
receiving a kidney. But if we know that patients with common
HLA types are likely to have a higher graft survival, should we
deprive them of the grafts only to be fair to the others? If we
did, both patient groups would have poorly matched transplants
with a 78% one-year graft survival.
My position would be this: now that we can successfully find
kidneys for patients with the common HLA types, even though
these patients may be few in number, they should be able to
benefit from the new advance. Moreover, we are maximizing
the usable life from donor kidneys in these patients. For the
other patients with rare HLA types, many other protocols are
being developed that are said to yield results comparable to
those with matched transplants. Thus, patients with uncommon
HLA types should not be severely disadvantaged; they only
will have to wait a little longer.
Black patients also might have to wait a little longer. But
again, this should not be used as an argument to prevent other
patients who have well-matched organs from receiving them. If
the social problem of obtaining more black donors is solved,
then black patients too will be able to receive 6-antigen-
matched kidneys.
DR. RICHARD J. ROHRER (Chief of Transplant Surgery, New
England Medical Center): We certainly have a commitment to
matching and sharing in New England, utilizing the New
England Organ Bank. Here at New England Medical Center,
we have been the beneficiary of the sort of system you have
been promulgating. In fact, we have received a 6-antigen-
matched kidney from Seattle, and a liver from Anchorage. At
transplant surgeons' meetings, however, I get the sense that
although no one disagrees about the desirability of matching,
there are concerns about the social and practical aspects of
implementing a distribution system based exclusively on match-
ing. Could you comment on the practical aspects involved in
implementing your proposed system?
DR. TERASAKI: On a practical level, I realize the difficulties
associated with national kidney sharing. These issues include
longer ischemia times required for organ shipping, difficult
communications across different time zones, viability of kid-
neys received from other centers, and the difficulties with
crossmatching. Yet, as I said, transplants with superior graft
survival have been obtained despite these hurdles. A 10%
higher one-year graft survival with a projected 20% higher
survival at 10 years is certainly worthwhile for the patients and
for the utilization of this scarce resource. The extra dollar cost
is probably less than that for most immunosuppressive drugs. If
we consider cost-effectiveness, I believe there is no question
that the benefits from the 6-antigen matches far outweigh the
costs.
Perhaps the more difficult question to be addressed is,
"should the matching scheme be extended to include a wider
range of categories of good matches?" We have proposed that
one-half of the kidneys salvaged in the United States be shared
on the basis of matching and the UNOS point system. The most
serious practical concern for surgeons is interference with the
kidney utilization patterns that have been established for the
past 20 years. Surgeons would like assurance that their loss of
control of the kidney will not result in fewer transplants. They
would also like to see equitable sharing among centers.
The "keep one, share one" proposal is a compromise be-
tween the patient-driven and center-driven methods of alloca-
tion. We believe that with the appropriate number of donation
points given for donation of kidneys, equitable sharing can be
attained without compromising the patient's opportunity for
receiving the best-matched kidney. The superior kidney sur-
vival rate should more than compensate for the extra effort
involved in sharing. Well-matched transplants, as shown here,
virtually eliminate one of the strongest factors, the "center
effect."
DR. HARRINGTON: David Taube recently presented a
Nephrology Forum on the usefulness of immunoadsorption in
transplantation of sensitized patients, using immunoadsorption
alone or immunoadsorption in combination with immunosup-
pressive agents [16]. How would you compare this technique
with the UNOS 6-antigen-match strategy? His results show an
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approximate 80% to 90% one-year success rate without regard
to matching.
DR. TERASAKI: Taube's group has pioneered immunoadsorp-
tion for highly sensitized patients. The 80% to 90% one-year
graft survival figure probably is not based on a large number of
patients. Nevertheless, immunoadsorption is an important av-
enue that warrants further investigation. Many highly sensitized
patients will be unable to receive well-matched grafts, so we
will need to find a way to provide kidneys to those patients.
With concurrent immunosuppression, antibodies may be re-
moved without rebound of antibody formation, and with the
destruction of clones that made the antibody, the method
promulgated by Taube and his colleagues in London should be
quite valuable.
The 6-antigen match for highly sensitized patients, however,
is the ideal solution for those who can get the right donor. These
patients will have no incompatibilities against which to react,
and their antibodies will be harmless against the graft. In
addition, as with the unsensitized patients, their grafts will
survive longer simply by virtue of being well matched.
MR. FREDERICK Lo (Student, Harvard Medical School,
Boston, Massachusetts): You mentioned early in your talk that
heart transplantation requires special attention to typing and
histocompatibility. Given the attempts that have been made to
transplant the heart of a baboon into a human being, are there
special tissue typing techniques that need to be used? Could
you also comment on the overall concept of using such xe-
nografts?
DR. TERASAKI: Researchers have considered xenografts for
heart transplants because there probably will never be enough
cadaver donors to supply all the patients who could benefit from
a heart transplant. Because using primates as a source of hearts
would generally be socially unacceptable, some reseachers
have suggested using pigs. These animals are used for food, so
one wouldn't anticipate any objections to using them as a
source of organ transplants.
I have not been active in this approach because of the
relatively poor long-term outcome of allografted hearts. Today,
even with cyclosporine, about 40% of human heart grafts are
lost within 5 years. We hope that the development of a cold
storage solution will permit matched heart transplants in the
future.
DR. HARRINGTON: You have shown us nice data demonstrat-
ing that a 6-antigen-matched kidney improves the outcome for
10% of patients. You also showed us that a number of other
factors, such as kidney size, recipient size, and age of donor,
affect outcome as well. Should UNOS begin to take those other
factors into account in matching available kidneys with recipi-
ents?
DR. TERASAK!: Yes, we feel that extremes in size matching
for kidney transplants should be avoided. Placing small kidneys
into large recipients has resulted in low graft survival rates. We
should have some mechanisms in place whereby such trans-
plants could be avoided.
DR. LEVEY: Not all of our 2-haplotype living-related trans-
plants or our 6-antigen-matched cadaver transplants succeed.
Although there are many reasons for graft failure, certainly
some losses are due to immunologic rejections. What are the
inciting events in those rejections?
DR. TERAsAKI: You are quite right! Even well-matched
transplants fail. With HLA-identical sibling donor grafts, there
are constant transplant losses, with a half-life of about 20 to 50
years. Moreover, in the bone marrow transplant experience,
one-half of the patients with HLA-identical donors develop
graft-versus-host disease [17]. We have plenty of evidence that
HLA is not the only histocompatibility determinant [17]. It is
well documented that the H2 system is dominant in the mouse,
but many other minor loci affect histocompatibility [181. Un-
doubtedly humans also have other loci. One of those postulated
is the Lewis system [17]. Thus far, the evidence regarding the
importance of this system is unclear. Many other attempts are
being made to use target cells (other than lymphocytes) with the
hope of finding antigens other than HLA. Monocytes, endothe-
hal cells, and skin cells have been investigated [191. Very little
of this work has been confirmed, however. We are still some
distance from having another system as well defined as the
HLA system, but there is little doubt that HLA must be the
major histocompatibility system, just as H2 is for the mouse.
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